Encorafenib/Cetuximab Plus Chemo Drives ORR Improvement in BRAF V600E+ mCRC
Treatment with the combination of encorafenib (Braftovi), cetuximab (Erbitux), and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) led to an statistically significant and clinically meaningful improvement in overall response rate (ORR) vs mFOLFOX6 …